1[1]Keck PE Jr,Strakowski SM,McElroy SL.The efficacy of atypical antipsychotics in the treatment of depressive symptoms,hostility,and suicidality in patients with schizophrenia.J Clin Psychiatry,2000,61 suppl3:4-9.
2[2]Nelson EB,Rielage E,Welge JA,et al.An open trial of olanza-pine in the treatment of patients with psychotic depression.Ann Clin Psychiatry,2001,13(3):147-151.
4[5]Fontaine R,OntiverosA,Elie R,et al.A double-blind comparison of nefazodone imipramine,and placebo in major depression.J Clin Psychiatry,1994,55(6):234-241.
5[6]Knable MB,Weinberger DR.Dopamine,the prefrontal cortex and schizophrenia.J Psychopharmacol,1997,11(2):123-131.
6[7]Bymaster FP,Rasmussen K,Calligaro DO,et al.In vitro and in vivo biochemistry of olanzopine:a novel,a typical antipsychotic drug.J Clin Psychiatry,1997,58(10)28-36.
2Martin, C, Genduso L, Revicki D, et al. Quality of life outcomes of olanzapine, a new atypical antipsychotic agent(abstract) [M]. Presented at the Winter workshop on schizophrenia. 1996,3 Crans-montana, Switzerland.
3TohenM,Jacob TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study[J]. Arch Gen Psychiatry, 2000,57 (9) : 841-9.
4Tohen M,Shelton R, Tollefson GD, et al. 01anzapine Plus Fluoxetine: double-blind and open-label results in the treatment-resistant major depressive disorder[C]. Presented at the 12^th annual meeting of the European College of Neuropsychopharmacology. London England, 1999,21-25.
